Xie E R, Liu C, Ni Y J, Gao D F, Deng J
Department of Cardiovascular Medicine, Second Affiliated Hospital of Xi'an Jiaotng University, Xi'an 710000, China.
Zhonghua Xin Xue Guan Bing Za Zhi. 2021 Dec 24;49(12):1227-1234. doi: 10.3760/cma.j.cn112148-20211008-00857.
To systematically evaluate the efficacy of drug coated balloon (DCB) versus conventional balloon in the treatment of coronary de novo bifurcation lesions. The databases of PubMed, Embase, Cochrane Library, Web of science, CNKI (China National Knowledge Infrastructure), Wanfang database, VIP, China Biology Medicine disc, Chinese clinical trial registry, American clinical trial registry and cardiovascular related websites until September 2020 were retrieved for collecting the randomized controlled trials (RCT) comparing DCB versus conventional balloon in the treatment of coronary de novo bifurcation lesions. The risk of bias of included studies was assessed using the Cochrane risk assessment tool. The meta-analysis was performed by using Revman 5.3 and Stata 14.0 software. Seven RCTs with a total of 613 patients were included in this meta-analysis. Among the included studies, 4 articles reached the low risk of bias, and the other 3 articles reached the medium risk of bias. The results of meta-analysis showed that there was no significant difference in the major adverse cardiac events (=0.65, 95% 0.39-1.08, =0.10), myocardial infarction (=0.68, 95% 0.25-1.80, =0.43), target lesion revascularization (=0.94, 95% 0.53-1.67, =0.83) between DCB group and conventional balloon group. Late lumen loss of side branch was less in the DCB group than that in the conventional balloon group (=-0.25, 95% -0.41--0.09, <0.01) and the risk of side branch restenosis was also lower in the DCB group than that in the conventional balloon group (=0.47, 95% 0.22-0.98, <0.05). However, subgroup analysis showed that the conclusions of domestic studies and foreign studies on late lumen loss and side branch restenosis were inconsistent. The meta-analysis based on domestic literature showed that the risk of side branch restenosis after DCB treatment was lower compared with conventional balloon group (=0.29, 95% 0.15-0.57, <0.05), while this parameter derived from foreign literatures remained unchanged between two groups (=0.53). The meta-analysis results of domestic literature showed that late lumen loss in DCB group was less than that in conventional balloon group (=-0.32, 95% -0.51--0.13, <0.05), but this phenomenon was not observed in foreign literatures (=0.30). The use of DCB in the treatment of coronary de novo bifurcation lesions has the potential to reduce the rate of restenosis and late lumen loss of side branch compared with conventional balloon group. However, due to the limitation on quantity, quality and results of published studies, more high-quality and large scale RCTs are still needed to confirm these findings.
系统评价药物涂层球囊(DCB)与传统球囊治疗冠状动脉初发分叉病变的疗效。检索截至2020年9月的PubMed、Embase、Cochrane图书馆、Web of science、中国知网(CNKI)、万方数据库、维普数据库、中国生物医学文献数据库、中国临床试验注册中心、美国临床试验注册中心及心血管相关网站,收集比较DCB与传统球囊治疗冠状动脉初发分叉病变的随机对照试验(RCT)。采用Cochrane风险评估工具评估纳入研究的偏倚风险。使用Revman 5.3和Stata 14.0软件进行荟萃分析。本荟萃分析纳入7项RCT,共613例患者。纳入研究中,4篇文章达到低偏倚风险,另3篇文章达到中偏倚风险。荟萃分析结果显示,DCB组与传统球囊组在主要不良心脏事件(=0.65,95% 0.39 - 1.08,=0.10)、心肌梗死(=0.68,95% 0.25 - 1.80,=0.43)、靶病变血运重建(=0.94,95% 0.53 - 1.67,=0.83)方面无显著差异。DCB组边支的晚期管腔丢失少于传统球囊组(=-0.25,95% -0.41 - -0.09,<0.01),且DCB组边支再狭窄风险也低于传统球囊组(=0.47,95% 0.22 - 0.98,<0.05)。然而,亚组分析显示,国内外研究关于晚期管腔丢失和边支再狭窄的结论不一致。基于国内文献的荟萃分析显示,DCB治疗后边支再狭窄风险低于传统球囊组(=0.29,95% 0.15 - 0.57,<0.05),而国外文献得出的该参数在两组间无变化(=0.53)。国内文献的荟萃分析结果显示,DCB组晚期管腔丢失少于传统球囊组(=-0.32,95% -0.51 - -0.13,<0.05),但国外文献未观察到这一现象(=0.